Neoadjuvant Olaparib Combo Fails to Surpass Carboplatin/Paclitaxel in HER2– Early Breast Cancer

Article

Long-term clinical data failed to show a benefit of neoadjuvant olaparib (Lynparza) plus paclitaxel vs carboplatin plus paclitaxel in patients with HER2-negative early breast cancer with homologous recombination deficiency.

Peter A. Fasching, MD

Peter A. Fasching, MD

Long-term clinical data failed to show a benefit of neoadjuvant olaparib (Lynparza) plus paclitaxel vs carboplatin plus paclitaxel in patients with HER2-negative early breast cancer with homologous recombination deficiency (HRD). Results with a median follow-up of 49.8 months from GeparOLA (NCT02789332) were presented at the 2022 San Antonio Breast Cancer Symposium.1

At a median follow-up of 49.8 months (range, 0.1-69.1) the 4-year invasive disease-free survival (iDFS) rate with olaparib plus paclitaxel (n = 69) was 76.0% vs 88.5% among 37 patients who received carboplatin vs paclitaxel. The unadjusted HR was 2.86 (95% CI, 0.83-9.90) and the adjusted HR for nodal status and germline mutational status was 3.6 (95% CI, 1.02-12.7).1

Further, the 4-year locoregional recurrence rates were higher following treatment with olaparib and paclitaxel (10.3%) compared with carboplatin and paclitaxel (4.9%).

Additional long-term efficacy end points included distant disease-free survival (DDFS) and overall survival (OS). The 4-year DDFS rate with olaparib/paclitaxel was 81.2% vs 93.4% with carboplatin/paclitaxel (HR, 3.03; 95% CI, 0.67-13.67; log-rank P = .1290). The 4-year OS rate was 89.2% with the olaparib combination vs 96.6% with carboplatin (HR, 3.27; 95% CI, 0.39-27.20; log-rank P = .2444).1

“[GeparOLA] was a small study with a low event rate,” Peter A. Fasching, MD, a professor in the Department of Obstetrics and Gynecology at the University Hospital Erlangen in Germany, said in a summary of the data. “It might be hypothesized that patients with a mutation, olaparib may replace platinum, keeping in mind that the toxicity profile was more favorable [for olaparib vs carboplatin/paclitaxel].”

Germline/somatic BRCA mutations were reported among 55.9% of patients in the olaparib arm (n = 38) and 56.8% of patients in the carboplatin/paclitaxel arm (n = 21). Outcomes were comparable with long-term follow-up in this subgroup for olaparib vs carboplatin/paclitaxel (HR, 1.16; 95% CI, 0.30-4.49; log-rank P = .8303).1 “For patients who had no mutation in the tumor or the germline—[all of whom] were HRD high—then there is a similar event rate for the olaparib-treated patients [vs those with BRCA-mutant disease (7 events each)], but these patients treated with olaparib had an excellent prognosis.”

“There was no further subgroup that would indicate a difference, it was only the BRCA mutation status and, maybe related to that, age where patients younger than 40 years were in favor of the olaparib treatment [HR, 0.408; 95% CI, 0.25-6.62; P = .0529],” Fasching said.

The study included patients with early-stage HER2-negative disease that had an HRD-high tumor, defined as having a known germline or somatic BRCA1/2 mutation or a high HRD score via MyChoice assay (score ≥ 42). Patients were randomly assigned 2:1 to receive weekly paclitaxel (80 mg/m2) plus olaparib at 100 mg twice daily or the same regimen of paclitaxel plus carboplatin area under the curve 2 weekly. Both arms also received epirubicin/cyclophosphamide at 90 mg/m2 and 600 mg/m2, respectively, every 2 or 3 weeks.

Patients were not permitted to enroll if they had prior treatment with a PARP inhibitor. A total of 106 patients were included in the intention-to-treat population. “For the interpretation of the data it might be important to memorize that there was a disbalance in nodal positivity,” Fasching said. “In the platinum arm, 45.7% of patients had a nodal-positive status and in the olaparib arm there was only [approximately] 25%.”

“It’s important to realize that the inclusion [criteria] allowed both: either a tumor or germline mutation or HRD score high. Almost all patients had a tumor with a high HRD score; however, not all of them were mutated with regard to the BRCA genes,” Fasching said.

Of the enrolled population, 96 patients had a high HRD score. Among these patients, 46.2% had a mutation, 43.4% were intact, and 1 patient had insufficient quality o quantity of DNA available for measurement. Further, 3 patients had HRD low score all of whom had BRCA-mutant disease and 7 patients were not measurable for HRD status.

Other baseline characteristics were well balanced with a median age of 47.0 years (range, 25.0-71.0), approximately 60% of patients in both arms having cT2 disease status, and approximately 27% of patients having estrogen receptor– and/or progesterone receptor–positive disease. A Ki-67 index of greater than 20% was reported for 91.3% of patients in the olaparib arm vs 86.5% in the carboplatin/paclitaxel arm.1,2

Pathological complete response (pCR) rate, the primary end point of the study, was previously reported in prior reports.2 The pCR rate was 55.1% (90% CI, 44.5%-65.3%) with olaparib vs 48.6% (90% CI, 34.3%-63.2%) with carboplatin/paclitaxel. The pCR rates were the same for patients with germline/somatic BRCA mutations who received olaparib (n = 35) and carboplatin (n = 20) at 60%. There was a benefit observed with olaparib among the 30 patients with wild-type disease with a pCR of 50.0% vs 37.5% for those who received carboplatin/paclitaxel (n = 16).

Fasching noted that larger trials are needed to assess the use of olaparib further in patients with germline or somatic BRCA mutations and the role of neoadjuvant platinum-containing chemotherapy for patients without mutations.

References

  1. Fasching PA, Schmatloch S, Hauke J, et al. Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency – long-term survival of the GeparOLA study. Presented at 2022 San Antonio Breast Cancer Symposium; December 6-10, 2022; San Antonio, TX. Abstract GS5-02.
  2. Fasching PA, Link T, Hauke J, et al. Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study). Ann Oncol. 2021;32(1):49-57. doi:10.1016/j.annonc.2020.10.471
Related Videos
Video 1 - "HR+/HER2- Early-Stage Breast Cancer: Background and Risk Stratification "
Don S. Dizon, MD
Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD
Patrick I. Borgen, MD
Henry Kuerer, MD, PhD, FACS, CMQ
Kari Hacker, MD, PhD, NYU Grossman School of Medicine
Janos L. Tanyi, MD, PhD, associate professor, Obstetrics and Gynecology, Hospital of the University of Pennsylvania